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Kristin Benjaminsen Borch1*, Eiliv Lund1, Tonje Braaten1 and Elisabete Weiderpass1,2,3,4Abstract
Background: The relationship between physical activity (PA) throughout life and the risk of postmenopausal breast
cancer overall and by estrogen receptor (ER) and progesterone receptor (PR) status, has been reported, but without
consistent results. The present study aimed to investigate PA from young age to adulthood in participants of the
Norwegian Women and Cancer (NOWAC) Study, in order to determine whether changes in PA level affect the risk
of postmenopausal breast cancer.
Methods: 1767 invasive breast cancer cases were identified among 80,202 postmenopausal participants of the
NOWAC Study during 8.2 years of median follow-up. PA levels at age 14 years, 30 years and at cohort enrollment
were obtained via a self-administered questionnaire. Multivariate Cox proportional hazard regression models were
used to estimate relative risks and 95% confidence intervals of the risk of postmenopausal breast cancer overall and
by ER/PR status.
Results: Risk of postmenopausal breast cancer overall and by ER/PR status was not associated with physical activity
level at enrollment. Women with a low PA level at age 30 had an increased risk of ER+/PR + breast tumors (P for
trend = 0.04) compared to women with a moderate physical activity level at age 30. Women with a low physical
activity level at all three periods of life had a 20% significantly reduced risk of postmenopausal breast cancer, as
well as a reduced risk of ER+/PR + and ER+/PR- breast tumors, compared with women who maintained a moderate
physical activity level. However, when analyses were corrected for multiple tests, the result was no longer
statistically significant. The findings were consistent over strata of age, body mass index and use of hormone
replacement therapy.
Conclusions: The study results from this large Norwegian cohort do not support an association between physical
activity at different periods of life and the risk of postmenopausal breast cancer.
Keywords: Physical activity, Breast cancer, Hormone receptor status, Norway, WomenBackground
Breast cancer is the most frequent cancer type among
women worldwide in terms of both incidence and mortal-
ity [1], and comprises one-quarter of all incident female
cancers in Norway [2]. Research has shown evidence of an
inverse relationship between physical activity (PA) and the
risk of postmenopausal breast cancer [3], with an average
observed risk reduction of 25% when comparing the most* Correspondence: kristin.benjaminsen.borch@uit.no
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reproduction in any medium, provided the orwith the least physically active women in both case–
control and cohort studies [4]. However, these findings
are not completely consistent; some prospective studies
have found either no relationship [5-8], or an increased
risk of postmenopausal breast cancer with increasing
amount of PA [9-11]. Despite the heterogeneity be-
tween studies on the topic, in their joint Second Expert
Report published in 2007 [12], and in updates from
2008 [13] and 2010 [14], the World Cancer Research
Fund and the American Institute for Cancer Research
concluded that PA probably reduces the risk of post-
menopausal breast cancer. A recent meta-analysis of 31td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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reduced risk of overall breast cancer of 12%. It further
concluded that this reduction is consistent across cat-
egories of menopausal status, body mass index (BMI),
hormone receptor status of tumor, tumor stage, type
and intensity of PA, and the periods of life in which PA
was reported [15]. However, there is some evidence that
the impact of lifestyle factors like PA on breast cancer
risk may vary by tumor characteristics, such as estrogen
receptor (ER) and progesterone receptor (PR) status
[4]. Moreover, studies on the association between PA at
different periods of life and the risk of postmenopausal
breast cancer have shown inconsistent results [3]. Only a
few studies included data on PA from young age to early
adulthood, i.e. from age 14 to 24, and this data mainly
reflected recreational or leisure PA [8,16-20]. None of
these studies found an inverse relationship, except one
case–control study which found a weak inverse relation-
ship between PA and risk of postmenopausal breast can-
cer [20]. Assessment of PA from young age to adulthood
can give important insight into how PA early in life affects
the risk of postmenopausal breast cancer.
In 2005, Margolis et al. analyzed the relationship be-
tween risk of premenopausal breast cancer and PA at
different periods of life in the Women’s Lifestyle and
Health Study. The Women’s Lifestyle and Health Study
is a prospective study of women in Norway and Sweden
[9], and includes the cohort of the Norwegian Women
and Cancer (NOWAC) Study. To complement this
work, the aim of the present report was to investigate
PA from young age to adulthood in participants of the
NOWAC study, to determine whether changes in PA
level affect the risk of postmenopausal breast cancer
overall and by ER/PR status.
Results
A total of 80,202 postmenopausal women from the
NOWAC study were followed for an average of 8.2 years,Table 1 Physical activity (PA) level and changes in PA level ac
postmenopausal women in the Norwegian Women and Cance
N Very low Low
At age 14a 77 623 2.2 12.1
At age 30a 78 477 1.7 12.2
At enrollment 80 202 5.2 20.9
Inactive-no change Active to
Age 14 to age 30 77 272 5.3 8.7
Age 14 to enrollment 77 623 4.7 21.4
Age 30 to enrollment 78 477 8.3 17.8
aMissing at age 14, 3.2%; age 30, 2.2%, compared to enrollment.
bInactive: very low or low PA level. Active: Moderate, high or very high PA level.constituting 648,731 person-years. Mean age at enrollment
for the study sample was 48 years. During follow-up, 1,767
women were diagnosed with breast cancer (mean age at
diagnosis: 59.7 years). Information on ER status was avail-
able for 79% of breast cancer cases; of these 83% were
ER + and 17% were ER-. PR status was available for 79% of
breast cancer cases, of which 63% were PR + and 37% were
PR-. Seventy-four percent of the women reported moder-
ate, high or very high PA levels at enrollment. This pro-
portion was even higher for the same PA levels at age
14 years (85.7%) and age 30 years (86.0%) (Table 1).
Among women who reported being inactive at age 14,
5.3% were still inactive at age 30, 77.1% who reported be-
ing active at age 14, were still active at age 30, and 8.7%
went from active at age 14 to inactive at age 30. Of the
women who reported being active at age 14, 64.3% were
still active at enrollment, 21.4% went from active to in-
active and 4.7% were inactive at age 14 and at enrollment
(Table 1).
BMI at enrollment was inversely associated with being
active at enrollment. Physically active women were over-
represented among never and former smokers, and
physically active women who were ever smokers tended
to smoke less cigarettes per day, had lower alcohol con-
sumption, used less hormone replacement therapy and
reported less cardiovascular disease and diabetes com-
pared to inactive women. Physically active and inactive
women had similar ages at menarche, first birth and
menopause, and a similar history of oral contraceptive
use (Table 2).
Risk of postmenopausal breast cancer and PA level at age
14, age 30 and at enrollment
In adjusted multivariable models, there was no associ-
ation between PA level at enrollment or at age 30 and
risk of postmenopausal breast cancer (Table 3). In con-
trast, compared to women with a moderate PA level
at age 14, women with a low PA level at age 14 had aross the three periods of life among 80,202
r Study
PA level (%)




Changes in PA levelb (%)




Table 2 Characteristics of the study sample at enrollment by physical activity (PA) level among 80,202
postmenopausal women from the Norwegian Women and Cancer Study
PA level
Very low Low Moderate High Very high
N 4196 16 773 33 538 20 564 5131
Age (years) 49.1 48.8 48.3 48.1 47.5
Duration of education (years) 11.3 12.2 12.3 12.4 11.6
Weight (kg) 70.8 68.8 66.1 64.5 63.1
Height (cm) 165.7 166.2 166.2 166.4 166.0
Body mass index (kg/m2) 25.8 24.9 23.9 23.3 22.9
Smoking status:
Never smoker 29.5 34.8 36.2 35.9 33.1
Former smoker 29.6 31.0 32.6 34.6 32.5
Current smoker 41.0 34.2 31.3 29.5 34.2
Pack-years (in former and current smokers) 8.5 6.5 5.5 5.2 5.6
Alcohol consumption (g/day) 3.5 3.5 3.4 3.5 3.1
Age at menarche 13.2 13.3 13.3 13.3 13.4
Oral contraceptive use (ever) 46.2 45.0 45.2 44.7 46.5
Age at first birth (years) 23.4 23.9 23.9 23.9 23.5
Nulliparous 10.8 9.0 8.1 8.0 7.6
Age at menopause (years) 47.6 48.3 48.4 48.3 48.1
Hormone replacement therapy use (current) 27.9 29.0 27.6 28.1 24.5
Self-reported cardiovascular disease (yes) 9.1 5.4 3.9 3.8 4.4
Self-reported diabetes (yes) 3.0 1.7 1.3 1.1 1.2
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risk, RR 0.80; 95% confidence interval, CI: 0.68, 0.95;
P for trend = 0.008). The same comparison using women
with a very low PA level at age 14 rendered an RR of 0.77
(95% CI: 0.54, 1.10).Table 3 Incidence of postmenopausal breast cancer and phys
enrollment among 80,202 postmenopausal women from the
Very low Low Mo
At age 14
N casesb 32 170 60
RR (95% CI)a 0.77 (0.54, 1.10) 0.80 (0.68, 0.95) 1.0
At age 30
N casesb 34 206 74
RR (95% CI)a 1.16 (0.82, 1.64) .99 (0.85, 1.16) 1.0
At enrollment
N cases 105 401 72
RR (95% CI)a 1.06 (0.86, 1.30) 1.05 (0.93, 1.19) 1.0
aMultivariable model with RR and 95% CI used the attained age as the underlying t
index, smoking status, smoking duration (pack years), age at menarche, use of oral
self-reported disease and history of breast cancer in the participant’s mother.
bThe total number of breast cancer does not add up due to by missing information
enrollment n = 77,623 and age 30 to enrollment n = 78,477.
RR: relative risks; CI: confidence intervals.ER/PR status and PA level at age 14, age 30 and at
enrollment
No statistically significant associations were observed
between PA level at enrollment and ER/PR status of
breast tumors (Table 4). At age 30 a significant trendical activity (PA) level at age 14, age 30 and at
Norwegian Women and Cancer Study
PA level
derate High Very high P trend
9 599 302
(ref) 1.02 (0.91, 1.14) 1.04 (0.90, 1.19) 0.008
6 548 189
(ref) 0.97 (0.87, 1.09) 0.91 (0.78, 1.08) 0.23
2 443 96
(ref) 1.04 (0.92, 1.17) 0.91 (0.73, 1.12) 0.40
ime variable. Covariates adjusted for in the model were height, body mass
contraceptives, age at first birth, parity, use of hormone replacement therapy,
on PA level at younger ages, age 14 to age 30 n = 77,272, age 14 to
Table 4 Estrogen receptor (ER) and progesterone receptor (PR) status of breast tumor and PA level at age 14, age 30
and at enrollment among 1,767 breast cancer cases in the Norwegian Women and Cancer Study
PA Level
ER/PR status N cases Very low Low Moderate High Very high P trend
ER+/PR+a 872 56 188 373 208 47
PA at enrollment 1.07 (0.81, 1.42) 0.94 (0.79, 1.12) 1.0 ref 0.95 (0.80, 1.12) 0.87 0(.65, 1.19) 0.49
PA at age 14 0.68 (0.40, 1.16) 0.74 (0.58, 0.95) 1.0 ref 1.02 (0.87, 1.20) 1.03 (0.85, 1.25) 0.02
PA at age 30 1.53 (1.00, 2.36) 1.10 (0.89, 1.40) 1.0 ref 0.95 (0.81, 1.12) 0.90 (0.71, 1.13) 0.04
ER+/PR-a 294 17 73 100 84 20
PA at enrollment 1.32 (0.78, 2.22) 1.43 (1.06, 1.94) 1.0 ref 1.40 (1.04, 1.87) 1.32 (0.81, 2.13) 0.98
PA at age 14 0.83 (0.36, 1.88) 0.62 (0.40, 0.98) 1.0 ref 0.92 (0.70, 1.22) 1.28 (0.93, 1.76) 0.02
PA at age 30 1.21 (0.53, 2.75) 0.84 (0.57, 1.26) 1.0 ref 1.00 (0.76, 1.30) 1.03 (0.70, 1.51) 0.68
ER-/PR-a 206 8 47 91 52 8
PA at enrollment 0.70 (0.34, 1.46) 1.03 (0.72, 1.47) 1.0 ref 0.94 (0.67, 1.32) 0.57 (0.28, 1.18) 0.51
PA at age 14 1.60 (0.73, 3.49) 1.06 (0.67, 1.70) 1.0 ref 1.10 (0.78, 1.54) 1.15 (0.76, 1.74) 0.94
PA at age 30 0.56 (0.14, 2.28) 0.78 (0.48, 1.27) 1.0 ref 0.90 (0.66, 1.24) 0.81 (0.50, 1.30) 0.97
aMultivariable model with relative risks and 95% confidence intervals used the attained age as the underlying time variable. Covariates adjusted for in the model
were height, body mass index, smoking status, smoking duration (pack years), age at menarche, use of oral contraceptives, age at first birth, parity, use of
hormone replacement therapy, self-reported disease and history of breast cancer in the participant’s mother.
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tumors was observed among women with a very low PA
level compared to those with a moderate PA level
(Table 4). However, compared to women with a mod-
erate PA level at age 14, those with a low PA level at
age 14 showed a trend of reduced risk for ER+/PR +
(P for trend = 0.02) and ER+/PR- (P for trend = 0.02)
breast tumors. Analysis of women with unknown ER/PR
status showed no significant associations with PA level
(data not shown). We found no indication that increasing
PA beyond the moderate PA level was inversely associated
with ER/PR status.
Overall risk of postmenopausal breast cancer and
changes in PA level
A significant increased risk of postmenopausal breast
cancer (RR 1.18; 95% CI: 1.00, 1.39) was found among
women who changed their PA level from active to in-
active between age 14 and age 30. Women who changed
their PA level in the opposite direction; i.e. from inactive
to active, had a significant reduced risk of postmeno-
pausal breast cancer (RR 0.81; 95% CI: 0.67, 0.97). In
contrast, women who were inactive at age 14 and age 30
had a significantly reduced risk of postmenopausal
breast cancer (RR 0.78; 95% CI: 0.62, 0.99). Women who
were inactive from age 14 to enrollment had a non-
significant reduced risk (RR 0.82; 95% CI: 0.64, 1.03),
compared to women who were active at all three periods
of life (Table 5). We did not detect any significant asso-
ciation between changes in PA level from age 30 to en-
rollment and risk of postmenopausal breast cancer, even
after stratification by age (data not shown).ER/PR status and changes in PA level
The analyses of ER/PR status and changes in PA level at
the three periods of life revealed a significant increased
risk of 43% for ER+/PR + breast tumors among women
who were active throughout all three periods of life
compared to women who went from being active to be-
ing inactive between age 14 and age 30 (Table 5). The
results also suggested that changing from inactive to ac-
tive between age 14 and age 30 (RR 0.74; 95% CI: 0.56,
0.97) and between age 14 and enrollment (RR 0.71; 95%
CI: 0.54, 0.93) protected against ER+/PR + breast tumors.
We found no evidence that changes in PA level had any
effect on ER+/PR- or ER-/PR- breast tumors (Table 5),
nor on breast tumors with unknown hormone receptor
status (data not shown).
Results from crude models were not significantly dif-
ferent than those from multivariate models (data not
shown). All multivariate models were adjusted for BMI,
but results were almost identical to those from models
without adjustment for BMI. Homogeneity tests con-
firmed that there were no statistical differences between
the magnitudes of the effect estimates. We assessed the
potential effect modification of BMI and hormone re-
placement therapy use by conducting stratified analyses.
These analyses revealed no statistically significant inter-
action of BMI or hormone replacement therapy use on
the relationship between PA level at enrollment or
changes in PA level and risk of postmenopausal breast
cancer overall, or by ER/PR status (data not shown). The
analyses stratified by different periods of enrollment did
not change the estimates (data not shown). Finally, the
Holms procedure for multiple testing showed that no
Table 5 Postmenopausal breast cancer risk overall and by estrogen receptor (ER) and progesterone receptor (PR)
status of breast tumors and changes in physical activity (PA) level among 1,767 breast cancer cases in the Norwegian
Women and Cancer Study
N cases Overall Breast cancer N casesa ER+/ PR+ N casesa ER+/ PR- N casesa ER-/PR-
Changes in PA levelb RR (95% CI)c RR (95% CI)c RR (95% CI)c
Age 14 to age 30
Inactive 75 0.78 (0.62, 0.99) 37 0.79 (0.56, 1.10) 9 0.53 (0.27, 1.03) 10 0.91 (0.48, 1.73)
Active to inactive 163 1.18 (1.0, 1.39) 96 1.43 (1.15, 1.78) 27 1.10 (0.74, 1.65) 11 0.72 (0.39, 1.32)
Inactive to active 125 0.81 (0.67,0 .97) 56 0.74 (0.56, 0.97) 20 0.73 (0.46, 1.15) 21 1.16 (0.73. 1.82)
Active 1334 1.0 ref 650 1.0 ref 229 1.0 ref 155 1.0 ref
Age 14 to enrollment
Inactive 72 0.82 (0.64, 1.03) 34 0.75 (0.53, 1.06) 9 0.63 (0.32, 1.24) 10 1.06 (0.56, 2.03)
Active to inactive 419 1.06 (0.95, 1.20) 203 1.00 (0.85, 1.18) 78 1.29 (0.98, 1.69) 44 1.07 (0.75, 1.52)
Inactive to active 130 0.79 (.66, 0.95) 59 0.71 (0.54, 0.93) 20 0.71 (0.45, 1.13) 21 1.12 (0.70, 1.77)
Active 1091 1.0 ref 550 1.0 ref 179 1.0 ref 124 1.0 ref
Age 30 to enrollment
Inactive 146 1.06 (0.89, 1.27) 79 1.15 (0.91, 1.46) 24 1.05 (0.69, 1.62) 11 0.72 (0.39, 1.33)
Active to inactive 347 1.04 (0.92, 1.18) 160 0.95 (0.79, 1.13) 64 1.27 (0.95, 1.69) 43 1.18 (0.83, 1.67)
Inactive to active 94 1.01 (0.82, 1.25) 55 1.19 (0.90, 1.57) 12 0.77 (0.43, 1.37) 11 1.01 (0.54, 1.87)
Active 1136 1.0 ref 562 1.0 ref 188 1.0 ref 136 1.0 ref
aThe total number of breast cancer does not add up caused by missing information on PA at younger ages, age 14 to age 30 n = 77,272, age 14 to enrollment
n = 77,623 and age 30 to enrollment n = 78,477.
bInactive: very low or low PA level, Active: moderate, high or very high PA level.
cThe multivariable model with RR and 95% CI used the attained age as the underlying time variable. Covariates adjusted for in the model were height, body mass
index, smoking status, duration of smoking (pack years), age at smoking initiation, age at menarche, use of oral contraceptives, age at first birth, parity, use of
hormone replacement therapy, self-reported disease and history of breast cancer in the participant’s mother.
RR: relative risks; CI: confidence intervals.
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ferent periods of life, or for different ER/PR status of
breast cancer tumors (data not shown).
Discussion
In this Norwegian cohort study, there was no consistent,
significant relationship between PA level and postmeno-
pausal breast cancer overall, or by ER/PR status. We
found an increased risk of postmenopausal breast cancer
overall, and of ER+/PR + breast tumors among women
who went from active to inactive between age 14 and
age 30. Furthermore, among women who changed from
inactive to active at the same ages, the opposite was true;
they had a decreased risk of postmenopausal breast can-
cer overall, and of ER+/PR + breast tumors compared to
women who remained physically active throughout all
three periods of life. Furthermore, we observed that
women with a very low PA level at age 30 had an in-
creased risk of ER+/PR + breast tumors compared to
women with a moderate PA level at the same age.
We also observed a statistically significant 20% reduc-
tion in the risk of postmenopausal breast cancer among
women with PA levels that were low at age 14, and
remained low throughout adulthood, as compared to
women who were either moderately active at age 14, orhad a moderately active lifestyle throughout adulthood
(i.e. at age 30 and at enrollment, which occurred between
the ages of 34 and 70 years). This unexpected association
was confirmed in the analysis of ER/PR status, which re-
vealed a decreased risk of ER+/PR + and ER+/PR- breast
tumors, though this was not the case for any of the other
combinations of ER/PR status. Taken together these find-
ings are inconsistent, and the risk of false-positive findings
only strengthens the uncertainty. Analysis for multiple
testing confirmed that none of the estimates reached stat-
istical significance, indicating that the inverse relationship
between PA level and postmenopausal breast cancer was
not strong in our study, and this must be considered when
reviewing the results.
The strengths of our study include the prospective co-
hort study design, long follow-up period and the com-
pleteness of follow-up data, which minimizes the potential
for selection bias. The ascertainment of postmenopausal
breast cancer and of the ER/PR status of breast tumors
was performed through the linkage to the national cancer
registry, which is virtually complete. Our study sample
was taken from a source population that is considered
representative of Norwegian general female population 34
to 70 years of age [21]. The availability of PA level over
different periods of life and the possibility to investigate
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The most important risk factors for postmenopausal
breast cancer were taken into account as confounding fac-
tors in our analyses, including age at menarche, age at first
birth, parity, age at menopause, history of breast cancer in
the participant’s mother, exogenous hormone use, BMI,
height, alcohol consumption [22,23] and cigarette smok-
ing [24-26]. Furthermore, a sensitivity analysis was carried
out in which we adjusted for BMI at age 18 years, which
minimized potential residual confounding of unmeasured,
or other unknown factors in the relationship under study.
Our study also has some limitations. The lack of a
clear risk pattern may be partly due to the fact that PA
level was self-reported, and collected all at once for three
different periods of life. Therefore this information was
based on the participant’s capability to recall PA levels
correctly; incorrect recall could have led to misclassifica-
tion that might have influenced the true exposure status
early in life. Moreover, the changes in PA level at age 14,
age 30 and at enrollment may not be entirely representa-
tive of the 15–20 years in between. Indeed, elderly
women have been shown to overestimate PA levels earl-
ier in life [27,28]. This would result in non-differential
misclassification, and could therefore bias the results to-
ward the null. Our measures to capture the effect of PA
on a specific disease may be considered crude, since
there was no information on type, duration, frequency
or intensity of PA. However, the PA level in the present
study covers the total amount of PA, and is meant to re-
flect a comprehensive measure. Finally, the low number of
women with very low PA levels at age 14 led to a low
number of breast cancer cases in this group, and reduced
the statistical power of the analysis. This also represents a
limitation of the study and should be considered when
evaluating the results.
ER and PR status was missing for 21% of the women
in the present analysis. Therefore analyses on ER/PR sta-
tus of breast tumors had less power than analyses on
postmenopausal breast cancer overall. Our choice of age
53 as a cut-off for age at menopause ended up excluding
women that were likely menopausal. Also, we used PA
levels reported at enrollment for all three time periods
for women who became postmenopausal during follow-
up (and thus were included only from that point in
time). Finally, lack of controlling for unknown factors,
and the fact that information on potential confounding
factors was only collected at enrollment, may have intro-
duced residual confounding.
The original aim of the NOWAC study was to investi-
gate the association between breast cancer and oral
contraceptive use, with no specific emphasis on PA other
than as a possible confounding factor. Although the cor-
relation between our PA measure and the reference
method [29] was modest, this same scale of PA level wasinversely associated with all-cause, cardiovascular and
cancer mortality in the NOWAC cohort, indicating a
face validity of sensitivity to detect major disease trends
and variations [30]. The internal validity of self-reported
information on use of oral contraceptives, parity, dur-
ation of education [31] and use of hormone replacement
therapy [32], has been investigated in the NOWAC Study,
and is considered valid.
Our results did not corroborate findings from other
studies that suggested PA protects against postmeno-
pausal breast cancer [4,7,18,33-38]. In a recent review of
73 studies (both case–control and prospective cohort
studies), only 40% found a statistically significant risk re-
duction, which was 25% on average when comparing
women with high and low PA levels [4]. Furthermore, the
strongest inverse associations were found with recre-
ational PA, PA throughout life, PA after menopause, and
PA of moderate and vigorous intensity performed regu-
larly [4,39]. A recent meta-analysis of 31 prospective stud-
ies found an inverse relationship between PA and breast
cancer, with 12% risk reduction and a dose–response rela-
tionship. This association was stronger for women with a
BMI less than 25 kg/m2, premenopausal women, and for
ER-/PR- breast tumors [15]. However, our results on post-
menopausal breast cancer are in agreement with previous
investigations on postmenopausal breast cancer or hor-
mone receptor status and total PA by self-administered
questionnaire, which detected no association, or only
weak associations after adjusting for confounding factors
[5,6,40-45]. In a previous prospective study of Norwegian
women, the findings in postmenopausal women did not
confirm any effect of PA during leisure time or at work
[46]. Others have found a modest inverse effect of total
PA level [47]. Conversely, another investigation has found
a non-significant trend of increased risk of postmeno-
pausal breast cancer with increasing PA [10].
In principle, our findings indicate the same trend, sug-
gesting that low PA level at age 14 has a modest protect-
ive effect on the risk of postmenopausal breast cancer
overall, and on ER+/PR + breast tumors. These results
are in contrast with those of The Women’s Health Initia-
tive, which investigated PA at age 18 years and risk of
postmenopausal breast cancer and found no association
either overall or by hormone receptor status. However,
they found an inverse effect of PA at age 35 [18]. A
case–control study on PA early in life found that strenu-
ous PA at age 14–22 was associated with 45% reduction
in the risk of postmenopausal breast cancer [16], whereas
a prospective study failed to detect any effect of sports at
young ages [8]. A review examining PA in adolescence
and young adulthood found an almost 20% risk reduction
with moderate/vigorous recreational PA, despite variation
in the populations and the inclusion of both case–control
and prospective cohort designs [48].There are conflicting
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should take place to reduce the risk of postmenopausal
breast cancer. One study found limited support for an in-
verse association between PA during adolescence and
throughout life and the risk of postmenopausal breast can-
cer [17]. Others have found that recreational PA during
the reproductive and postmenopausal years is the most
relevant period for reducing the risk of postmenopausal
breast cancer [49], as well as sustained PA throughout
life [4,17,50]. Studies using a single point of PA measure
did not find any association [40,43,44], which strengthens
the argument that baseline PA is not sufficient to predict
the risk of postmenopausal breast cancer over longer pe-
riods. The long latency between carcinogenic exposures
and the manifestation of breast cancer [51,52] supports
the argument that PA patterns need to be assessed over a
woman’s lifetime.
The inverse relationship of PA on hormone receptor-
positive breast tumors has been reported [7,38,53,54].
We observed a weak inverse relationship between PA
and an increased risk of ER+/PR + breast tumor status,
when very low and low PA levels were compared with
the moderate PA level at age 30. This association is in
line with findings from the majority of investigations
published to-date [3,38,47,55,56], and strengthens the
hypothesis that PA may act through hormonal pathways,
by reducing the cumulative exposure to ovarian hormones
[39,57]. Studies have reported an inverse relationship for
the combination of ER+/PR+, ER+/PR-, ER-/PR- status
and high PA, but not for moderate PA levels [7], whereas
others have found stronger associations for ER- breast
tumors [36,58], and an inverse relationship of PA with
both ER+/− and PR+/− breast tumors [18,54,59,60].
PA is likely to act through multiple pathways, which could
explain the inconsistency in previous findings, together
with a limited power to analyze ER and PR status in breast
tumors and PA [38,53,54,61], and the heterogeneity
assessing PA which makes it difficult to compare results
between studies.
Some studies have confirmed that the association be-
tween PA and breast cancer is not modified by BMI
[5,19,34,35,37,47,62-64], but not all of them [18,19,40,65].
Several studies reported no modification effect of use of
hormone replacement therapy [18,19,37,47,65], though a
few did find an effect [36,45]. Although BMI and use of
hormone replacement therapy may be related to breast
cancer, the aforementioned results suggest that PA is inde-
pendently associated with breast cancer.
Conclusion
Our study did not detect a consistent inverse effect of
PA on the risk of postmenopausal breast cancer in this
large cohort of Norwegian women. For future research,
information on PA during follow-up is essential. Despitethe results of the present study, PA remains an import-
ant modifiable lifestyle factor with the potential to re-
duce the risk of postmenopausal breast cancer.
Methods
The NOWAC Study has been previously described in
detail [21,31]. In short, at cohort enrollment (1991,
1996–1997 and 2003–2004), participating women com-
pleted an extensive questionnaire, including questions
on PA, dietary habits, smoking status and habits, alcohol
consumption, education, reproductive history, height
and weight, exogenous hormone use, and previous ill-
nesses. The Regional Ethical Committee and the Norwe-
gian Data Inspectorate approved the NOWAC Study. All
women gave written informed consent prior to their par-
ticipation in the study.
Study sample
A total of 122,857 women who participated in the
NOWAC Study were initially eligible for the present
analysis. We excluded all women with prevalent cancer
at enrollment (n = 4620), those who died within the first
year of follow-up (n = 265) and those with missing infor-
mation on PA level at enrollment (n = 12,313). Women
who reported their age at menopause at the time of
enrollment or during follow-up (available from second
questionnaire for some of the women) were categorized
as postmenopausal. All other women, including those with
missing information on age at menopause, were catego-
rized as postmenopausal once they reached 53 years of
age during follow-up, i.e., 53 years of age was used as a
proxy for age at menopause. This cut-off was based on the
definition used in the Million Women Study, and later in
the NOWAC study [66-68]. Based on these criteria, we
excluded all premenopausal women (n = 12,235). We fur-
ther excluded women with missing information on any
relevant covariates. This left a final study sample of 80,202
postmenopausal women; of these 3.2% had missing infor-
mation on PA levels at age 14, and 2.2% at age 30.
Self-reported PA level
PA level at age 14, age 30 and at enrollment (ages 34–70)
was assessed by self-report on an ordinal scale of 1
to 10. PA was defined in the questionnaire as follows:
“By physical activity we mean activity both at work
and outside work, at home, as well as training/exercise
and other physical activity, such as walking, etc. Please
mark the number that best describes your level of
physical activity; 1 being very low and 10 being very
high”. The PA scale used for this study has recently
been validated for the assessment at enrollment [29], and
refers to the total amount of PA across different domains,
including frequency, duration and intensity in one global
score. Moderate, but significant (P <0.001) Spearman’s
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between the PA level at enrollment and concurrent
outcomes from criterion measures of a combined
sensor monitoring heart rate and movement. The
scale ranged from 1 (very low) to 10 (very high), and
corresponded to mean values of 0.8 and 3.4 hours/day of
moderate/vigorous PA, respectively, with a linear increase
(P for trend <0.001), and appeared valid to rank PA level
in a Norwegian population of women [29]. The PA levels
at age 14 and 30 could not be validated in a concurrent
design. The PA levels used in the present analysis were
collapsed as follows: very low (levels 1 and 2), low (levels 3
and 4), moderate (levels 5 and 6), high (levels 7 and 8) and
very high (levels 9 and 10), which were created to
resemble those used in earlier analyses [9,69]. We further
categorized women based on changes in PA level over
time, from age 14 to age 30 and further to enrollment
(age 34–70 years). We then dichotomized the PA levels
very low or low as inactive, and PA levels of moderate,
high and very high as active for each period of life
considered. We compared PA levels between age 14 and
age 30, age 14 and enrollment, and between age 30 and
enrollment. This led to four categories of changes in PA
level: those who remained inactive, those who went from
active to inactive, those who went from inactive to active,
and those who remained active.
Covariates
Information collected at enrollment included age, dur-
ation of education, weight, height, BMI, smoking history
(including smoking status: never, former, current; dur-
ation and quantity of cigarettes smoked/day (pack-years)
and age at smoking initiation, alcohol consumption
(grams/day), age at menarche, use of oral contraceptives,
age at first birth, parity, age at menopause and use of
hormone replacement therapy. Self-reported illnesses in-
cluded cardiovascular diseases (history of heart failure,
myocardial infarction, angina pectoris and hypertension)
and diabetes mellitus. Information on history of breast
cancer in the participant’s mother (yes/no) was also col-
lected. Information on prevalent cancer was obtained
through linkage to the Cancer Registry of Norway.
Follow-up
Person-years were calculated from start of follow-up for
women who were postmenopausal at study enrollment,
and from age at menopause (either reported or 53 years)
for all other women, until date of diagnosis, emigration,
death, or end of the study period (December 31st 2009),
whichever occurred first. We obtained information
on date of death or emigration from the Norwegian
National Population Register, and on cancer diagnosis
and ER and PR status of breast tumors through linkage to
the Cancer Registry of Norway. Cancer diagnoses werecoded according to the 10th revision of the International
Statistical Classification of Diseases, Injuries and Causes
of Death. The main endpoint in this study was incidence
of invasive breast cancer (C50), and ER and PR status
of breast tumors was classified as follows: ER+/PR+,
ER+/PR-, ER-/PR+, ER-/PR- and unknown.
Statistical analysis
Characteristics of the study participants were examined
by PA level and breast cancer incidence. Cox propor-
tional hazard regression models were used to estimate
the hazard ratio as a measure of relative risk (RR) with
corresponding 95% confidence intervals (CI). In specific
analyses of ER and PR status, breast tumors without a
specific ER or PR status were considered censored ob-
servations. There were too few ER-/PR + breast tumors
to allow for a meaningful analysis, therefore no corre-
sponding results are presented. Tests for trend were esti-
mated using the collapsed five-level scale and entered as
a continuous term in the Cox proportional hazards re-
gression models.
The proportional hazard assumption was checked
using Schoenfeld residuals and Kaplan-Meier log (−log)
survival plots, which suggested no evidence of deviation
from proportionality. In the multivariable Cox regression
models, confounders adjusted for in the different models
were height (cm), BMI (kg/m2), smoking status (never,
former, current), smoking habits, which included smok-
ing duration (years), quantity (pack-years as the total
number of years a smoker smoked 20 cigarettes/day)
and age at smoking initiation combined as one variable
(age at smoking initiation ≥20 years and current smoker;
age at smoking initiation ≥20 years and former smoker;
age at smoking initiation <20 years, 0–19 pack-years and
current smoker; age at smoking initiation <20 years and
former smoker; and finally ≥20 pack-years, age at smok-
ing initiation <20 years and current smoker), alcohol
consumption (none, 0.1-3.9, 4.0-10.0 and >10.0 grams/
day), age at menarche (years), use of oral contraceptives
(ever/never), age at first birth (<20, 20–25, >25 years),
parity (nulliparous, 1, 2, ≥3 children), use of hormone
replacement therapy (current/never), self-reported car-
diovascular disease (yes/no) and diabetes mellitus (yes/
no), and history of breast cancer in the participant’s
mother (yes/no).
Duration of education and total energy intake were
not included in the final models, as they were not appre-
ciably related to breast cancer after adjustment for the
other confounders in the NOWAC cohort [70] or the
present analysis. In each comparison, the group with
moderate PA level was set as the reference group. In the
analysis of changes in PA level, the group of women who
remained active over all three periods of life was set as
the reference group. Analyses were done for a crude
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and without BMI as a covariate. Additionally the models
were stratified by BMI (<25 and ≥25 kg/m2), use of hor-
mone replacement therapy (ever/never) and age (30–39,
40–49, 50–59, and ≥60 years) for change in PA between
age 30 and enrollment. Use of hormone replacement
therapy may modify the association between BMI and
risk of postmenopausal breast cancer [71,72], and fur-
ther influence the effect estimation of PA level on the
risk of postmenopausal breast cancer in the models that
included BMI. Therefore this was examined before the
analyses were undertaken. No significant mean differ-
ences were found between BMI in never users compared
to ever users of hormone replacement therapy, thus fur-
ther stratification was not performed.
Homogeneity of the effect estimates in the different
models was evaluated using the Wald test to compare
different regression estimates. Information regarding
BMI at 18 years of age was available for 95% of the par-
ticipants, thus we carried out a sensitivity analysis; BMI
at age 18 has no effect on out risk estimates, therefore
this variable was not included in the main models. Fi-
nally, we conducted Holm’s multiple-test procedure to
protect against false-positive conclusions when analyzing
subgroups of breast cancer. Analyses were conducted
using STATA version 12.0, special edition (StataCorp,
College Station, Texas, USA), with all statistical tests
two-sided and conducted at the 0.05 significance level.
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